References
- National Heart, Lung and Blood Institute. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. NIH Publication No 97–4053. National Institutes of Health, Bethesda, MD October, 1997
- National Asthma Education and Prevention Program: Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 97–4051. National Institutes of Health, Bethesda, MD February, 1997
- Haahtela T. Airway remodelling takes place in asthma—what are the clinical implications. Clin Exp Allergy 1997; 27: 351
- Pedersen S. Early use of inhaled steroids in children with asthma. Clin Exp Allergy 1997; 26: 995
- Hayman G. Why the environment matters. Br J Clin Pract 1995; 79: 2
- Leach C L, Davidson P, Heilman J. Improved lung deposition and decreased oro-pharyngeal deposition with a new CFC-free beclomethasone metered dose inhaler. Am J Respir Crit Care Med 1997, 4 Part 2: A667
- Harrison L I, Donnell D, Simmons J L. Twenty-eight-day double blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J Pharm Pharmacol 1996; 48: 596
- Donnell D, Harrison L I, Ward S. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur J Clin Res 1995; 48: 473
- June D S, Schultz D W. Improved performance characteristics of CFC-free aerosol MDIs. J Aerosol Med 1995; 8: 91
- Leach C, Boudreau R, Davidson P. Improved airway targeting with CFC-free HFA-BDP MDI compared to CFC. Eur Respir J 1998; 12: 1346
- National Heart, Lung and Blood Institute, National Institutes of Health. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. NIH Publication No. 95–3659. National Institutes of Health, Bethesda, MD January, 1995
- Kerstjens H AM, Overbeek S E, Schouten J P. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Resp J 1993; 6: 868
- Lipworth B J. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993; 58: 173
- Davies R, Simmons J, Stampone P, Donnell D. Equivalent asthma symptom control of 1500 MCG beclomethasone dipropionate (BDP) achieved with 800 MCG BDP from fine aerosol solution. Eur Respir J 1996; 23: 254s, Suppl
- Gross G, Thompson P J, Chervinsky P. Hydro-fluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999; 115: 343
- Busse W, Brazinsky S, Jacobson K. Efficacy response of inhaled beclomethasone in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 105: 1215
- Busse W, Schmitt K, Colice G. Improved asthma symptom control with 100 μg/day HFA-BDP but not with 100 μg / day CFC-BDP. Am J Respir Crit Care Med 1998; 157(3)A405
- Lorentzon S, Boe J, Eriksson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990; 45: 733
- Sheffer A L, LaForce C, Chervinsky P. and the Fluticasone Propionate Asthma Study Group: Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Earn Pract 1996; 42: 369
- Fahy J V, Boushey H A. Effect of low dose beclomethasone dipropionate on asthma control and airway inflammation. Eur Respir J 1998; 11: 1240